|
Peter Goss tries mass-tort, toxic exposure and complex commercial disputes, and focuses his practice on defending product liability claims against medical manufacturers. Peter has served on trial teams for Solvay Pharmaceuticals, Pfizer and Sorin CarboMedics and has won dismissals for clients such as DuPont, Roche, Wyeth and Johnson & Johnson. The Legal 500 describes him as a "seasoned litigator providing solid trial experience and guidance."
A keen interest in scientific evidence drives much of Peter's practice. He has partnered with leading researchers in a variety of medical and scientific disciplines, including pathology, neurology, toxicology, cardiology, psychiatry, cardiac surgery, drug delivery systems, biomaterials, and biomechanical engineering. His collaborations with key opinion leaders have produced several winning Daubert motions and provided critical leverage in bringing high-stakes medical product and toxic tort litigation to a successful close.
Peter represents a broad range of health-care industry clients, including pharmaceutical firms, medical device manufacturers, and makers of biologics and dietary supplements. He has defended claims involving Parkinson's medications, diet drugs, hormone products, antidepressants, hip and knee implants, spinal fixation devices, cardiac surgery products and heart-lung bypass equipment. He often counsels clients on product liability risk management strategies and FDA compliance issues.
A frequent speaker and author on scientific evidence and other issues affecting his clients, Peter is co-author of two Daubert treatises: "Scientific Evidence in the 8th Circuit," in Scientific Evidence Review (ABA Press 2008), and "Scientific Evidence in Pesticide Litigation," in Pesticide Litigation Manual (West 2008). He also co-wrote "Clearing Away The Junk: Court-Appointed Experts, Scientifically Marginal Evidence, and the Silicone Gel Breast Implant Litigation," 56 Food & Drug L.J. 227 (2001), for which he received a Burton Award For Legal Achievement. | 